logo-loader

Globo to participate in high-profile Parkinson's Disease project

Last updated: 01:20 30 Dec 2014 EST, First published: 02:20 30 Dec 2014 EST

globo_byod350px_optimised_54a2542323b23

Bring-your-own-device enterprise software specialist Globo (LON:GBO) is to participate in a European mobile health (mHealth) project.

The company will be part of a consortium of European Universities and companies that has been awarded a European Union framework programme grant of €4.3 million for research into Parkinson's Disease management using mHealth technology.

The programme will use unobtrusive mobile devices to capture data from Parkinson's Disease sufferers that can then be analysed, with the results of the analysis informing the provision of medication.

Globo will support the research, offering its GO!Enterprise technology with a view to potentially expand the resulting product and systems beyond the Parkinson's Disease manager programme.

Globo also intends to support the commercialisation of the product. Globo's specific element of the programme will receive €300,000 in funding, the company revealed.

Expressing the company's pride in being chosen to participate in the high-profile programme, founder and chief executive Costis Papadimitrakopoulos said: "This exciting project complements our ambitions in the emerging field of mHealth, illustrates the trust placed in the underlying security and consistency of our technology, and demonstrates the applicability of the GO!Enterprise platform to systems based on the Internet of Things."

Shares were up 2.4% at 38.9p in morning trading.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

35 minutes ago